Follicular Lymphoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：209頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Follicular Lymphoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Follicular Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Follicular Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Follicular Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Follicular Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Follicular Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Follicular Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Follicular Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Follicular Lymphoma - Overview 11
Pipeline Products for Follicular Lymphoma - Comparative Analysis 12
Follicular Lymphoma - Therapeutics under Development by Companies 13
Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
Follicular Lymphoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Follicular Lymphoma - Products under Development by Companies 21
Follicular Lymphoma - Products under Investigation by Universities/Institutes 23
Follicular Lymphoma - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Boehringer Ingelheim GmbH 25
F. Hoffmann-La Roche Ltd. 26
Gilead Sciences, Inc. 27
Merck & Co., Inc. 28
Infinity Pharmaceuticals, Inc. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
ImmunoGen, Inc. 32
Genmab A/S 33
Sandoz Inc. 34
Celgene Corporation 35
Bayer AG 36
Immunomedics, Inc. 37
Accentia Biopharmaceuticals, Inc. 38
Portola Pharmaceuticals, Inc. 39
Pharmacyclics, Inc. 40
Memgen, LLC. 41
ProNAi Therapeutics, Inc. 42
AmpliMed Corporation 43
CureTech Ltd. 44
Xiamen Amoytop Biotech Co., Ltd. 45
MENTRIK Biotech, LLC 46
AbbVie Inc. 47
Follicular Lymphoma - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Target 49
Assessment by Mechanism of Action 54
Assessment by Route of Administration 59
Assessment by Molecule Type 62
Drug Profiles 65
bortezomib - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ibrutinib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
dasiprotimut T - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
lenalidomide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ofatumumab - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ocaratuzumab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
rituximab biosimilar - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
ixazomib citrate - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
mocetinostat - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
abexinostat hydrochloride - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
idelalisib - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ISF-35 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
imexon - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
pidilizumab - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
epratuzumab - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
CTL-019 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
vorinostat - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
buparlisib hydrochloride - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
PNT-2258 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
duvelisib - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
GS-9973 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
PRT-2070 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
DNA Fusion Vaccines - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
obinutuzumab - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
ulocuplumab - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
GM-K562 Cell Vaccine - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Autologous Recombinant Idiotypic Vaccine - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
NSC-678515 - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
IMGN-529 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
ABT-199 - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
rituximab biosimilar - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
rituximab biosimilar - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
interferon alfa-2b biosimilar - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
interferon alfa-2b - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
ABT-737 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Andrographolide - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Follicular Lymphoma - Recent Pipeline Updates 139
Follicular Lymphoma - Dormant Projects 195
Follicular Lymphoma - Discontinued Products 197
Follicular Lymphoma - Product Development Milestones 198
Featured News & Press Releases 198
Jan 13, 2014: European Medicines Agency Accepts Marketing Authorization Application for Biovest’s Cancer Vaccine for Treatment of Non-Hodgkin’s Follicular Lymphoma 198
Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Zevalin at the 55th Annual Meeting of the American Society of Hematology 199
Aug 14, 2013: Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma 199
Jun 03, 2013: MethylGene Presents Clinical Data On Mocetinostat At ASCO 2013 Annual Meeting 200
May 28, 2013: MethylGene To Present Mocetinostat Data At 2013 ASCO Annual Meeting 201
May 15, 2013: Janssen Oncology Announces Presentation Of Data On Ibrutinib At 2013 ASCO Annual Meeting 201
Mar 07, 2013: Biovest Files Recapitalization Plan To Strengthen Balance Sheet And Advance Commercialization Strategy For BiovaxID Cancer Vaccine 202
Dec 11, 2012: Pharmacyclics Announces Updated Results For BTK Inhibitor Ibrutinib At American Society Of Hematology Annual Meeting 203
Dec 11, 2012: Celgene Presents Data Evaluating Combination Treatments Including Revlimid Plus Antibody Therapies In Patients With Various Forms Of Non-Hodgkin Lymphoma At ASH 2012 205
Dec 08, 2012: Roche Reports Positive Results From Two Studies Of MabThera Given By Subcutaneous Injection 206
Appendix 208
Methodology 208
Coverage 208
Secondary Research 208
Primary Research 208
Expert Panel Validation 208
Contact Us 209
Disclaimer 209
List of Tables
Number of Products under Development for Follicular Lymphoma, H1 2014 11
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 24
Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 25
Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 26
Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 27
Follicular Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 28
Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 29
Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 30
Follicular Lymphoma - Pipeline by Novartis AG, H1 2014 31
Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H1 2014 32
Follicular Lymphoma - Pipeline by Genmab A/S, H1 2014 33
Follicular Lymphoma - Pipeline by Sandoz Inc., H1 2014 34
Follicular Lymphoma - Pipeline by Celgene Corporation, H1 2014 35
Follicular Lymphoma - Pipeline by Bayer AG, H1 2014 36
Follicular Lymphoma - Pipeline by Immunomedics, Inc., H1 2014 37
Follicular Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014 38
Follicular Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 39
Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 40
Follicular Lymphoma - Pipeline by Memgen, LLC., H1 2014 41
Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2014 42
Follicular Lymphoma - Pipeline by AmpliMed Corporation, H1 2014 43
Follicular Lymphoma - Pipeline by CureTech Ltd., H1 2014 44
Follicular Lymphoma - Pipeline by Xiamen Amoytop Biotech Co., Ltd., H1 2014 45
Follicular Lymphoma - Pipeline by MENTRIK Biotech, LLC, H1 2014 46
Follicular Lymphoma - Pipeline by AbbVie Inc., H1 2014 47
Assessment by Monotherapy Products, H1 2014 48
Number of Products by Stage and Target, H1 2014 51
Number of Products by Stage and Mechanism of Action, H1 2014 56
Number of Products by Stage and Route of Administration, H1 2014 61
Number of Products by Stage and Molecule Type, H1 2014 64
Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 139
Follicular Lymphoma - Dormant Projects, H1 2014 195
Follicular Lymphoma - Dormant Projects (Contd..1), H1 2014 196
Follicular Lymphoma - Discontinued Products, H1 2014 197
List of Figures
Number of Products under Development for Follicular Lymphoma, H1 2014 11
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Products, H1 2014 20
Assessment by Monotherapy Products, H1 2014 48
Number of Products by Top 10 Target, H1 2014 49
Number of Products by Stage and Top 10 Target, H1 2014 50
Number of Products by Top 10 Mechanism of Action, H1 2014 54
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 55
Number of Products by Top 10 Route of Administration, H1 2014 59
Number of Products by Stage and Top 10 Route of Administration, H1 2014 60
Number of Products by Top 10 Molecule Type, H1 2014 62
Number of Products by Stage and Top 10 Molecule Type, H1 2014 63
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Follicular Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Follicular Lymphoma - Overview 11
Pipeline Products for Follicular Lymphoma - Comparative Analysis 12
Follicular Lymphoma - Therapeutics under Development by Companies 13
Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
Follicular Lymphoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Follicular Lymphoma - Products under Development by Companies 21
Follicular Lymphoma - Products under Investigation by Universities/Institutes 23
Follicular Lymphoma - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Boehringer Ingelheim GmbH 25
F. Hoffmann-La Roche Ltd. 26
Gilead Sciences, Inc. 27
Merck & Co., Inc. 28
Infinity Pharmaceuticals, Inc. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
ImmunoGen, Inc. 32
Genmab A/S 33
Sandoz Inc. 34
Celgene Corporation 35
Bayer AG 36
Immunomedics, Inc. 37
Accentia Biopharmaceuticals, Inc. 38
Portola Pharmaceuticals, Inc. 39
Pharmacyclics, Inc. 40
Memgen, LLC. 41
ProNAi Therapeutics, Inc. 42
AmpliMed Corporation 43
CureTech Ltd. 44
Xiamen Amoytop Biotech Co., Ltd. 45
MENTRIK Biotech, LLC 46
AbbVie Inc. 47
Follicular Lymphoma - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Target 49
Assessment by Mechanism of Action 54
Assessment by Route of Administration 59
Assessment by Molecule Type 62
Drug Profiles 65
bortezomib - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ibrutinib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
dasiprotimut T - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
lenalidomide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ofatumumab - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ocaratuzumab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
rituximab biosimilar - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
ixazomib citrate - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
mocetinostat - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
abexinostat hydrochloride - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
idelalisib - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ISF-35 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
imexon - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
pidilizumab - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
epratuzumab - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
CTL-019 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
vorinostat - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
buparlisib hydrochloride - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
PNT-2258 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
duvelisib - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
GS-9973 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
PRT-2070 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
DNA Fusion Vaccines - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
obinutuzumab - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
ulocuplumab - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
GM-K562 Cell Vaccine - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Autologous Recombinant Idiotypic Vaccine - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
NSC-678515 - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
IMGN-529 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
ABT-199 - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
rituximab biosimilar - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
rituximab biosimilar - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
interferon alfa-2b biosimilar - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
interferon alfa-2b - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
ABT-737 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Andrographolide - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Follicular Lymphoma - Recent Pipeline Updates 139
Follicular Lymphoma - Dormant Projects 195
Follicular Lymphoma - Discontinued Products 197
Follicular Lymphoma - Product Development Milestones 198
Featured News & Press Releases 198
Jan 13, 2014: European Medicines Agency Accepts Marketing Authorization Application for Biovest’s Cancer Vaccine for Treatment of Non-Hodgkin’s Follicular Lymphoma 198
Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Zevalin at the 55th Annual Meeting of the American Society of Hematology 199
Aug 14, 2013: Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma 199
Jun 03, 2013: MethylGene Presents Clinical Data On Mocetinostat At ASCO 2013 Annual Meeting 200
May 28, 2013: MethylGene To Present Mocetinostat Data At 2013 ASCO Annual Meeting 201
May 15, 2013: Janssen Oncology Announces Presentation Of Data On Ibrutinib At 2013 ASCO Annual Meeting 201
Mar 07, 2013: Biovest Files Recapitalization Plan To Strengthen Balance Sheet And Advance Commercialization Strategy For BiovaxID Cancer Vaccine 202
Dec 11, 2012: Pharmacyclics Announces Updated Results For BTK Inhibitor Ibrutinib At American Society Of Hematology Annual Meeting 203
Dec 11, 2012: Celgene Presents Data Evaluating Combination Treatments Including Revlimid Plus Antibody Therapies In Patients With Various Forms Of Non-Hodgkin Lymphoma At ASH 2012 205
Dec 08, 2012: Roche Reports Positive Results From Two Studies Of MabThera Given By Subcutaneous Injection 206
Appendix 208
Methodology 208
Coverage 208
Secondary Research 208
Primary Research 208
Expert Panel Validation 208
Contact Us 209
Disclaimer 209
List of Tables
Number of Products under Development for Follicular Lymphoma, H1 2014 11
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 24
Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 25
Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 26
Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 27
Follicular Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 28
Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 29
Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 30
Follicular Lymphoma - Pipeline by Novartis AG, H1 2014 31
Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H1 2014 32
Follicular Lymphoma - Pipeline by Genmab A/S, H1 2014 33
Follicular Lymphoma - Pipeline by Sandoz Inc., H1 2014 34
Follicular Lymphoma - Pipeline by Celgene Corporation, H1 2014 35
Follicular Lymphoma - Pipeline by Bayer AG, H1 2014 36
Follicular Lymphoma - Pipeline by Immunomedics, Inc., H1 2014 37
Follicular Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014 38
Follicular Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 39
Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 40
Follicular Lymphoma - Pipeline by Memgen, LLC., H1 2014 41
Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2014 42
Follicular Lymphoma - Pipeline by AmpliMed Corporation, H1 2014 43
Follicular Lymphoma - Pipeline by CureTech Ltd., H1 2014 44
Follicular Lymphoma - Pipeline by Xiamen Amoytop Biotech Co., Ltd., H1 2014 45
Follicular Lymphoma - Pipeline by MENTRIK Biotech, LLC, H1 2014 46
Follicular Lymphoma - Pipeline by AbbVie Inc., H1 2014 47
Assessment by Monotherapy Products, H1 2014 48
Number of Products by Stage and Target, H1 2014 51
Number of Products by Stage and Mechanism of Action, H1 2014 56
Number of Products by Stage and Route of Administration, H1 2014 61
Number of Products by Stage and Molecule Type, H1 2014 64
Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 139
Follicular Lymphoma - Dormant Projects, H1 2014 195
Follicular Lymphoma - Dormant Projects (Contd..1), H1 2014 196
Follicular Lymphoma - Discontinued Products, H1 2014 197
List of Figures
Number of Products under Development for Follicular Lymphoma, H1 2014 11
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Products, H1 2014 20
Assessment by Monotherapy Products, H1 2014 48
Number of Products by Top 10 Target, H1 2014 49
Number of Products by Stage and Top 10 Target, H1 2014 50
Number of Products by Top 10 Mechanism of Action, H1 2014 54
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 55
Number of Products by Top 10 Route of Administration, H1 2014 59
Number of Products by Stage and Top 10 Route of Administration, H1 2014 60
Number of Products by Top 10 Molecule Type, H1 2014 62
Number of Products by Stage and Top 10 Molecule Type, H1 2014 63
